Category: ALung Technologies Inc.
An FDA advisory panel recommends reclassifying extracorporeal membrane oxygenator therapy from the highest-risk category to the less-risky Class II designation.
An FDA panel yesterday recommended that the FDA reclassify membrane lung for long-term pulmonary support systems, or so-called extracorporeal membrane oxygenator circuits and accessories, from the highest-risk Class III category to the less burdensome Class II, with special controls.
ALung Technologies raises a nearly $16 million Series B1 round for its Hemolung respiratory assist device.
ALung Technologies said it raised a $15.8 million Series B1 round it plans to use to accelerate the commercialization of its Hemolung respiratory assist device.
The Pittsburgh-based medical device company said the round was led by Allos Ventures and included West Capital Partners, Birchmere Ventures, BlueTree Capital Group, PLSG Accelerator Fund, Smithfield Trust Company and several private investors.
ALung inches closer to topping off a $17 million fundraising round, with less than $2.3 million left to raise.
Pennsylvania medical device maker ALung Technologies is nearing the close of a $17 million equity funding round with about $14.7 million raised so far among 48 unnamed investors, according to an SEC filings.
The new report updated a fundraising effort that began in late March 2013, and ALung reported last month that it had hit the $9.5 million mark in the raise. Now it's got about 2.3 million left before putting a bow on this round.
ALung pulls in $9.5 million in an equity funding round it hopes will eventually bring in a total of $17 million for its Hemolung respiratory assist system.
ALung Technologies raised $9.5 million of a hoped-for $17 million for its Hemolung respiratory assist system, according to a regulatory filing.
The Pittsburgh-based medical device company is aiming to get the Hemolung device on the market here and in China.
ALung Technologies says it's going for a Chinese regulatory nod for its Hemolung respiratory assist device.
ALung Technologies said it's pursuing approval from Chinese regulatory authorities for its Hemolung respiratory assist system.
The Pittsburgh-based medical device company said it inked a deal with Curative Medical to seek approval for the Hemolung device from the China Food & Drug Administration.
The $372 million buyout of Navilyst medical is expected to add 8 cents per share to AngioDynamics' books during fiscal 2013; also, Orasi Medical closes up shop; Becton, Dickinson reveals medical device tax impact; Abiomed hits 52-week high; analysts' ups and downs; and the MassDevice.com Funding Roundup.
Financial projections from AngioDynamics (NSDQ:ANGO) about its $372 million deal to acquire Navilyst Medical show that it expects to reap some significant rewards from the merger over the short and long terms.
, Apollo Endosurgery
, Becton Dickinson & Co.
, Cardica Inc.
, Cerner Corp.
, iHear Medical
, InVivo Therapeutics Corp.
, Navilyst Medical Inc.
, Ohio Third Frontier
, Orasi Medical Inc.
, OrthoCor Medical Inc.
, Pyng Medical
, St. Jude Medical
, Steris Corp.
, Velomedix Inc.
, Abiomed Inc.
, ALung Technologies Inc.
, AngioDynamics Inc.
, Foundation Radiology Group